Johanna Ungerstedt | Karolinska Institutet

Stäng

Ett medicinskt universitet

Sök

Meny

Ett medicinskt universitet

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2024;99(1):e13333

No indication of aberrant neutrophil extracellular trap release in indolent or advanced systemic mastocytosis.

Rosell A; Karlström C; Dahlin JS; Boey D; Klimkowska M; Ax K; Thålin C; Ungerstedt J
Article: SCIENTIFIC REPORTS. 2023;13(1):21787

The functional and molecular impact of triamcinolone acetonide on primary human bone marrow mesenchymal stem cells.

Kumlin M; Ungerstedt J; Cai H; Leonard E; Felländer-Tsai L; Qian H
Journal article: HEMASPHERE. 2023;7(Suppl):e7796003

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE‐BLIND PLACEBO‐CONTROLLED PIONEER TRIAL

Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby‐Olsen S; George TI; Panse J; Alvarez‐Twose I; Radia D; Tashi T; Livideanu CB; Sabato V; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Ustun C; Schafhausen P; Bose P; Deangelo DJ; Rein L; Vachhani P; Triggiani M; Rafferty M; Butt N; Oh S; Wortmann F; Ungerstedt J; Taparia M; Kuykendall AT; Yi CA; Mattsson M; Shomali W; Giannetti M; Bidollari I; Lin H; Scherber R; Roche M; Akin C; Maurer M
Journal article: HEMASPHERE. 2023;7(Suppl):e790629d

P506: CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI‐CENTER PROSPECTIVE COHORT STUDY

Tesi B; Eriksson A; Baskin B; Lazarevic V; Deneberg S; Höglund M; Fogelstrand L; Ungerstedt J; Pandzic T; Tobiasson M; Garelius HG; Kuchinskaya E; Persson F; Ågerstam H; Uggla B; Hallböök H; Fioretos T; Thuresson A; Lehmann S; Ladenvall C; Barbany G; Vennström L; Ejerblad E; Cavelier L; Cammenga J; Jädersten M; Lindberg EH; Baliakas P
Article: BLOOD. 2023;142(1):73-89

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.

Dolinska M; Cai H; Månsson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-S; Deneberg S; Söderlund S; Jädersten M; Ungerstedt J; Tobiasson M; Östman A; Mustjoki S; Stenke L; Le Blanc K; Hellström-Lindberg E; Lehmann S; Ekblom M; Olsson-Strömberg U; Sigvardsson M; Qian H
Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2023;152(1):205-213

Proteomic and transcriptomic screening demonstrates increased mast cell-derived CCL23 in systemic mastocytosis.

Söderlund S; Boey D; van Midden W; Kjellander M; Ax K; Qian H; Dahlin JS; Ungerstedt J
Journal article: NEJM EVID. 2023;2(6):evidoa2200339

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby-Olsen S; George TI; Panse J; Alvarez-Twose I; Radia DH; Tashi T; Bulai Livideanu C; Sabato V; Heaney M; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Pongdee T; Barete S; Ustun C; Schwartz L; Ward BR; Schafhausen P; Vadas P; Bose P; DeAngelo DJ; Rein L; Vachhani P; Triggiani M; Bonadonna P; Rafferty M; Butt NM; Oh ST; Wortmann F; Ungerstedt J; Guilarte M; Taparia M; Kuykendall AT; Arana Yi C; Ogbogu P; Gaudy-Marqueste C; Mattsson M; Shomali W; Giannetti MP; Bidollari I; Lin H-M; Sulllivan E; Mar B; Scherber R; Roche M; Akin C; Maurer M
Journal article: LEUKEMIA RESEARCH. 2023;128:107256

UNDERSTANDING CMML BIOLOGY BY INTEGRATIVE ANALYSIS OF EXOME SEQUENCING, RNA SEQUENCING, AND METHYLOME IN A LARGE PATIENT COHORT

Kynning MK; Nannya Y; Todisco G; Yoshizato T; Tesi B; Mortera-Blanco T; Bjorklund A-C; Bruck O; Ohyashiki K; Ishikawa T; Ochi Y; Haferlach T; Mustjoki S; Hellstrom-Lindberg E; Ogawa S; Ungerstedt J
Article: EUROPEAN JOURNAL OF ONCOLOGY NURSING. 2022;60:102172

Living with systemic mastocytosis: Balancing between vulnerability and resilience: A qualitative study.

Levedahl KH; Nilsson A; Ungerstedt J; Hedström M
Article: LAKARTIDNINGEN. 2022;119:22024

[Two cases of VEXAS syndrome].

Gunnarsson K; Vivar Pomiano N; Tesi B; Tobiasson M; Creignou M; Ungerstedt J
Article: CANCERS. 2022;14(16):3942

Clinical Outcomes of Adults with Systemic Mastocytosis: A 15-Year Multidisciplinary Experience.

Ungerstedt J; Ljung C; Klimkowska M; Gülen T
Article: BLOOD ADVANCES. 2022;6(15):4439-4449

Single-cell transcriptomics reveals the identity and regulators of human mast cell progenitors.

Wu C; Boey D; Bril O; Grootens J; Vijayabaskar MS; Sorini C; Ekoff M; Wilson NK; Ungerstedt JS; Nilsson G; Dahlin JS
Article: BLOOD. 2022;139(20):3040-3057

Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression.

Cai H; Kondo M; Sandhow L; Xiao P; Johansson A-S; Sasaki T; Zawacka-Pankau J; Tryggvason K; Ungerstedt J; Walfridsson J; Ekblom M; Qian H
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(12):991.e1-991.e9

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.

Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jädersten M; Hellström-Lindberg E; Grønbæk K; Ljungman P; Friis LS
Article: LEUKEMIA. 2021;35(8):2371-2381

Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms.

Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.

Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
Article: LANCET HAEMATOLOGY. 2021;8(2):e135-e148

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.

Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo M-J; Melchardt T; Egle A; Viniou A-N; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
Article: CANCER RESEARCH. 2020;80(12):2441-2450

Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine.

Ohtani H; Ørskov AD; Helbo AS; Gillberg L; Liu M; Zhou W; Ungerstedt J; Hellström-Lindberg E; Sun W; Liang G; Jones PA; Grønbæk K
Article: ALLERGY. 2020;75(2):456-460

Demonstration of human mast cell progenitors in the bone marrow.

Salomonsson M; Ungerstedt J; Alvarado-Vazquez PA; Hallgren J
Article: ALLERGY. 2020;75(1):211-214

CD203c distinguishes the erythroid and mast cell-basophil differentiation trajectories among human FcεRI+ bone marrow progenitors.

Grootens J; Ungerstedt JS; Wu C; Hamberg Levedahl K; Nilsson G; Dahlin JS
Article: FRONTIERS IN IMMUNOLOGY. 2020;11:321

Localization-Specific Expression of CCR1 and CCR5 by Mast Cell Progenitors.

Salomonsson M; Dahlin JS; Ungerstedt J; Hallgren J
Journal article: HEMASPHERE. 2019;3(S1):220-221

PF535 CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2‐MUTATED NEOPLASMS

Todisco G; Creignou M; Guglielmelli P; Rumi E; Nannya Y; Galli A; Pietra D; Elena C; Bono E; Dimitriou M; Ungerstedt J; Vannucchi A; Hellström‐Lindberg E; Cazzola M; Ogawa S; Malcovati L
Journal article: HEMASPHERE. 2019;3(S1):374-375

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer L; Leisch M; Kouraklis A; Padron E; Maciejewski JP; Cirici BX; Kaivers J; Ungerstedt J; Sonja H; Peristera P; Hunter A; Mora E; Geissler K; Dimou M; Lorenzo MJJ; Kiesl D; Vyniou A; Patel BJ; Montserrat A; Valent P; Christoforos R; Bernal T; Galanopoulos A; Munoz MC; Bonadies N; Almeida A; Cermak J; Jerez A; Montoro J; Cortés A; Pita AA; Andrade BL; Hellstroem‐Lindberg E; Germing U; Sekeres M; List A; Symeonidis A; Sanz GF; Greil R
Article: EBIOMEDICINE. 2019;43:150-158

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.

Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini R-M; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
Article: FREE RADICAL BIOLOGY AND MEDICINE. 2018;117:247-257

Selenite and methylseleninic acid epigenetically affects distinct gene sets in myeloid leukemia: A genome wide epigenetic analysis.

Khalkar P; Ali HA; Codó P; Argelich ND; Martikainen A; Arzenani MK; Lehmann S; Walfridsson J; Ungerstedt J; Fernandes AP
Article: FRONTIERS IN ONCOLOGY. 2018;8:407

Methylseleninic Acid Sensitizes Ovarian Cancer Cells to T-Cell Mediated Killing by Decreasing PDL1 and VEGF Levels.

Nair D; Rådestad E; Khalkar P; Diaz-Argelich N; Schröder A; Klynning C; Ungerstedt J; Uhlin M; Fernandes AP
Article: NEPHRON. 2018;140(4):249-256

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.

Levin A; Nair D; Qureshi AR; Bárány P; Heimburger O; Anderstam B; Stenvinkel P; Bruchfeld A; Ungerstedt JS
Article: BLOOD. 2017;130(16):1785-1794

KIT signaling is dispensable for human mast cell progenitor development.

Dahlin JS; Ekoff M; Grootens J; Löf L; Amini R-M; Hagberg H; Ungerstedt JS; Olsson-Strömberg U; Nilsson G
Article: ONCOTARGET. 2017;8(17):28812-28825

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.

Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
Article: ONCOTARGET. 2017;8(6):9647-9659

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.

Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Article: ONCOTARGET. 2016;7(16):22103-22115

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jädersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellström-Lindberg E
Article: ONCOTARGET. 2016;7(6):6809-6823

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.

Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Article: BBA CLINICAL. 2015;4:14-20

Glutaredoxin mediated redox effects of coenzyme Q10 treatment in type 1 and type 2 diabetes patients.

Montano SJ; Grünler J; Nair D; Tekle M; Fernandes AP; Hua X; Holmgren A; Brismar K; Ungerstedt JS
Article: ACTA DIABETOLOGICA. 2014;51(2):225-232

Plasma glutaredoxin activity in healthy subjects and patients with abnormal glucose levels or overt type 2 diabetes.

Du Y; Zhang H; Montano S; Hegestam J; Ekberg NR; Holmgren A; Brismar K; Ungerstedt JS
Article: MEDICAL ONCOLOGY. 2012;29(4):2348-2358

Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution.

Nahi H; Remberger M; Machaczka M; Ungerstedt J; Mattson J; Ringden O; Le-Blanc K; Ljungman P; Hägglund H
Article: FREE RADICAL BIOLOGY AND MEDICINE. 2012;53(11):2002-2007

In vivo redox state of human thioredoxin and redox shift by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

Ungerstedt J; Du Y; Zhang H; Nair D; Holmgren A
Article: MEDICAL ONCOLOGY. 2012;29(3):2191-2199

Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery.

Ungerstedt JS; Watz E; Uttervall K; Johansson B-M; Wahlin BE; Näsman P; Ljungman P; Gruber A; Axdorph Nygell U; Nahi H
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2006;4(10):2164-2169

Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.

Castaman G; Rodeghiero F; Tosetto A; Cappelletti A; Baudo F; Eikenboom JCJ; Federici AB; Lethagen S; Linari S; Lusher J; Nishino M; Petrini P; Srivastava A; Ungerstedt JS
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2006;281(16):10691-10697

Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase.

Hashemy SI; Ungerstedt JS; Zahedi Avval F; Holmgren A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2005;102(3):673-678

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.

Ungerstedt JS; Sowa Y; Xu W-S; Shao Y; Dokmanovic M; Perez G; Ngo L; Holmgren A; Jiang X; Marks PA
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2003;1(12):2554-2560

Nicotinamide inhibits endotoxin-induced monocyte tissue factor expression.

Ungerstedt JS; Heimersson K; Söderström T; Hansson M
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2003;131(1):48-52

Nicotinamide is a potent inhibitor of proinflammatory cytokines.

Ungerstedt JS; Blömback M; Söderström T
Article: JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY. 2003;15(1):13-18

Clotting onset time may be a predictor of outcome in human brain injury: a pilot study.

Ungerstedt JS; Grenander A; Bredbacka S; Blombäck M
Article: THROMBOSIS RESEARCH. 2003;111(6):329-334

Bedside monitoring of coagulation activation after challenging healthy volunteers with intravenous endotoxin.

Ungerstedt JS; Soop A; Sollevi A; Blombäck M
Article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 2002;62(2):135-140

Measurement of blood and plasma coagulation time using free oscillating rheometry.

Ungerstedt JS; Kallner A; Blombäck M
Article: INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY. 2001;23(5):313-316

Evaluation of a new immunoturbidimetric test (Liatest antithrombin III) for determination of antithrombin antigen.

Antovic J; Söderström J; Karlman B; Blombäck M
Visa fler

Alla övriga publikationer

Editorial comment: HAEMATOLOGICA. 2023;108(7):1968-1971

Omalizumab alleviates pruritus in myeloproliferative neoplasms.

Ravn Landtblom A; Ungerstedt J; Hedlund A; Tobiasson M; Deneberg S; Jädersten M
Conference publication: LEUKEMIA RESEARCH. 2023;128:107257

TET2/SRSF2 STATUS AND THROMBOSIS ARE RELEVANT FOR PROGNOSIS IN CHRONIC MYELOMONOCYTIC LEUKEMIA -DATA FROM A POPULATION-BASED STUDY OF 155 PATIENTS

Kynning MK; Westerberg E; Forsell L; Creignou M; Berggren DM; Tesi B; Bernard E; Papaemmanuil E; Cavelier L; Valentini D; Hellstrom-Lindberg E; Ejerblad E; Ungerstedt J
Conference publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023;23:S398-S399

Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial

Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby-Olsen S; George TI; Panse J; Alvarez-Twose I; Radia DH; Tashi T; Livideanu CB; Sabato V; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Ustun C; Schafhausen P; Bose P; DeAngelo DJ; Rein L; Vachhani P; Triggiani M; Rafferty M; Butt NM; Oh ST; Wortmann F; Ungerstedt J; Taparia M; Kuykendall AT; Yi CA; Mattsson M; Shomali W; Giannetti MP; Bidollari I; Lin H-M; Scherber R; Roche M; Akin C; Maurer M
Conference publication: BLOOD. 2022;140:3014

Single-Cell Multi-Omics Analysis Reveals Hematopoiesis of Aberrant Mast Cells in Systemic Mastocytosis

Wu C; Boey D; Mo J; Papavasileiou S; Ungerstedt J; Xu M; Nilsson G; Dahlin JS
Preprint: BIORXIV. 2021

Single-cell transcriptomics reveals the identity and regulators of human mast cell progenitors

Wu C; Boey D; Bril O; Grootens J; Vijayabaskar MS; Sorini C; Ekoff M; Wilson N; Ungerstedt J; Nilsson G; Dahlin J
Conference publication: BLOOD. 2019;134:844

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez M-J; Kiesl D; Viniou N-A; Patel BJ; Sangerman MA; Valent P; Roubakis C; del Castillo TB; Galanopoulos A; Calabuig M; Bonadies N; de Almeida AM; Cermak J; Jerez A; Montoro J; Cortes A; Pita AA; Andrade BL; Lindberg EH; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Greil R
Conference publication: CANCER RESEARCH. 2019;79(13):3092

Activation of evolutionarily young transposable elements and the host innate immune system are linked to clinical response to 5-azacitidine

Ohtani H; Orskov AD; Helbo AS; Gillberg L; Liu M; Zhou W; Ungerstedt J; Hellstrom-Lindberg E; Sun W; Liang G; Jones PA; Gronbaek K
Editorial comment: HEMASPHERE. 2019;3(Suppl):131

Myelodysplastic syndromes.

Ungerstedt J
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2018;19(10):E3091-3091

Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.

Ungerstedt JS
Review: BLOOD ADVANCES. 2018;2(17):2273-2281

Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells.

Grootens J; Ungerstedt JS; Nilsson G; Dahlin JS
Preprint: BIORXIV. 2018

Single-cell analysis reveals the KIT D816V mutation in hematopoietic stem and progenitor cells in systemic mastocytosis

Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini R-M; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
Meeting abstract: BLOOD. 2016;128(22):1489

Functional and Molecular Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Patients with Myelodysplastic Syndrome with Ring Sideroblast

Dolinska M; Xiao P; Johansson A-S; Sandhow L; Kondo M; Bouderlique T; Ungerstedt J; Hellstrom-Lindberg E; Qian H
Conference publication: FREE RADICAL BIOLOGY AND MEDICINE. 2016;100:S119-S120

Biological Characterization of the Anti-Tumor Properties of Novel Dual-Target Inhibitors of Dihydrofolate Reductase and Thioredoxin Reductase

Chew E-H; Ng H-L; Kjellander M; Karuppasamy M; Chong AS-Y; Chui W-K; Ungerstedt J
Letter: LEUKEMIA. 2016;30(9):1953-1956

Detection of circulating mast cells in advanced systemic mastocytosis.

Dahlin JS; Ungerstedt JS; Grootens J; Sander B; Gülen T; Hägglund H; Nilsson G
Conference publication: HAEMATOLOGICA. 2016;101:70

MODEST EPIGENETIC EFFECT OF AZACITIDINE IN GENOME-WIDE MAPPING OF DNA METHYLATION, H3K9ME3, H3K18AC AND GENE EXPRESSION IN MDS PROGENITORS

Tobiasson M; Ali HA; Lennartsson A; Katayama S; Marabita F; Karimi M; Khrjutskhov K; Einarsdottir E; Jansson M; Ben Azenkoud A; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
Conference publication: BLOOD. 2015;126(23):2839

Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy

Tobiasson M; MeLornan D; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj AG; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
Conference publication: BLOOD. 2015;126(23):2398

Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia

Dolinska M; Klang J; Xiao P; Durgaryan A; Sandhow L; Johansson A-S; Kondo M; Deneberg S; Ungerstedt J; Le Blanc K; Stenke L; Ekblom M; Stromberg U; Mustjoki S; Lehmann S; Qian H
Conference publication: BLOOD. 2015;126(23):2834

Histone Deacetylase Inhibitor SAHA Mediates Epigenetic Silencing of KIT D816V Mutated Systemic Mastocytosis Primary Mast Cells and Selective Apoptosis of Mutated Mast Cells

Abdulkadir H; Grootens J; Kjellander M; Lindberg EH; Nilsson G; Ungerstedt J
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S69

IN VITRO AZACITIDINE CULTURE INDUCES DNA DEMETHYLATION AND INCREASED MRNA-LEVELS IN PRIMARY MDS PROGENITOR CELLS

Abdulkadir H; Tobiasson M; Lennartsson A; Katayama S; Marabita F; Karimi M; Qu Y; Einarsdottir E; Govdal M; Jansson M; Ben Azenkoud A; Lehmann S; Ekwall K; Kere J; Hellstom-Lindberg E; Ungerstedt J
Conference publication: HAEMATOLOGICA. 2015;100:776

DEVELOPMENT OF A PROGRESS TEST BASED ON THE EHA CURRICULUM AND EHA CV PASSPORT, USED FOR YEARLY EVALUATION OF HEMATOLOGY RESIDENCY IN SWEDEN

Ungerstedt J; Eriksson A; Olander E; Bergfelt E; Liljeholm M; Kristjanssdottir HL; Erger T; Erixon D; Isaksson C; Birgegard G
Conference publication: BLOOD. 2014;124(21):4613

Mutations in Histone Modulators and HOXA5 Methylation Levels Affects Survival in Azacitidine Treated MDS Patients

Tobiasson M; Karimi M; Dimitriou M; Qu Y; Lennartsson A; Ali HA; Unnikrishnan A; Jadersten M; Jansson M; Ben Azenkoud A; Pimanda JE; Ekwall K; Ungerstedt J; Lehmann S; Hellstrom-Lindberg E
Letter: LEUKEMIA. 2014;28(2):411-413

Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.

Grövdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellström-Lindberg E
Conference publication: HAEMATOLOGICA. 2014;99:788

DEVELOPMENT OF PROGRESS TEST BASED ON EHA CURRICULUM AND EHA CV PASSPORT, USED FOR YEARLY EVALUATION OF HEMATOLOGY RESIDENCY IN SWEDEN

Ungerstedt J; Eriksson A; Olander E; Theander J; Liljeholm M; Isaksson C; Birgegard G
Letter: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2004;2(5):838-839

Antithrombin antigen and activity in patients with acquired antithrombin deficiency-is there a difference?

Ungerstedt JS; Antovic J; Blombäck M; Bremme K; Johnsson H
Letter: BLOOD. 2002;99(6):2271-2272

Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?

Ungerstedt JS; Schulman S; Egberg N; Antovic J; Blombäck N
Visa fler

Forskningsbidrag

Deciphering the molecular pathogenesis of chronic myelomonocytic leukemia (CMML)

Swedish Cancer Society

1 January 2019
Systemic mastocytosis emergence mechanisms and identification of new markers for progress and transition in leukemia, as well as a first targeted treatment

Swedish Cancer Society

1 January 2018
Systemic mastocytosis emergence mechanisms and identification of new markers for progress and transition in leukemia, as well as a first targeted treatment

Swedish Cancer Society

1 January 2017
Systemic mastocytosis emergence mechanisms and identification of new markers for progress and transition in leukemia, as well as a first targeted treatment

Swedish Cancer Society

1 January 2016
Molecular pathogenesis in myelodysplastic syndromes and acute myeloid leukemia

Swedish Research Council

1 January 2013 - 31 December 2015
Molecular pathogenesis in myelodysplastic syndromes and acute myeloid leukemia

Swedish Research Council

1 January 2009 - 31 December 2012

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, hematologi, Karolinska Institutet, 2014
MEDICINE DOKTORSEXAMEN, INST F KIRURGISK VETENSKAP (K3), Karolinska Institutet, 2003
Läkarexamen, Karolinska Institutet, 2003

Nyheter från KI

Kalenderhändelser från KI